InnoCare and Keymed Usher in New Era of Treatment with First Subject Dosed in Trial of Revolutionary CCR8 Monoclonal Antibody ICP-B05

InnoCare Pharma (HKEX: 09969; SSE: 688428) and Keymed Biosciences (HKEX: 02162) made a joint announcement today: the first patient has been dosed with ICP-B05 (CM369), an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody that was developed through their joint venture, Tiannuojiancheng Pharma in China. This marks a major milestone in the development of this cutting-edge medication.

InnoCare and Keymed have joined forces to create ICP-B05, a groundbreaking new treatment option that can be used as a monotherapy or in combination with other therapies to fight a variety of cancers. This innovative new drug could be a game-changer in the fight against this deadly disease.

CM369 is a revolutionary immunotherapy that targets CCR8 on Tregs – a type of immune cell that suppresses the anti-tumor effect – and eradicates them through ADCC. This is more specific than other immunotherapies, as it preserves peripheral homeostasis while delivering optimal tumor-targeted Treg depletion and augmenting anti-tumor immunity in the tumor microenvironment. ICP-B05 is also an effective immunotherapy that selectively depletes Tregs, offering an innovative way to fight cancer.

Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, is thrilled to announce the addition of ICP-B05 to their large molecule pipeline in solid tumors. CCR8 is a highly promising immuno-oncology target and has the potential to be combined with other treatments to achieve synergistic effects. InnoCare is committed to accelerating the clinical development of this innovative drug and providing the best possible solutions to address unmet clinical needs and benefit those with solid tumors.

Dr. Bo Chen, Co-founder, Chairman and CEO of Keymed Biosciences, is passionate about the potential of CM369 to specifically target and eliminate tumor-infiltrating Treg cells, which could potentially offer a transformative solution for advanced tumor patients. With this in mind, Keymed Biosciences is committed to accelerating the clinical development of this promising therapy.

About InnoCare

InnoCare is revolutionizing the healthcare industry with its ground-breaking biopharmaceutical research and development. Our mission is to discover, develop, and commercialize groundbreaking treatments for cancers and autoimmune diseases that have yet to find effective treatments. Our international presence spans across Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, making InnoCare a global leader in the healthcare industry.

About Keymed Biosciences

Keymed Biosciences is a biotechnology company that harnesses the power of innovation to develop biological therapies and treatments for autoimmune and oncology diseases. Our integrated platform and comprehensive drug development program allows us to quickly and efficiently create, expand, and advance our diverse pipeline. Our reach is global, with branches in Beijing, Chengdu, Guangzhou, Shanghai, and Wuhan, enabling us to bring our cutting-edge therapies to the world.

Leave a Comment